RECEI NOV 1.9 TECH CENTER

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

in re Application of:

Goldberg et al.

Application No: 10/050,686

Filed:

January 16, 2002

For:

Compositions and Methods for

Treatment of Muscle Wasting

Examiner: Unassigned

Art Unit: 1646

Attorney Docket No.: HMV-070.01

## CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, postage prepaid, in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231 on: November 11, 2002.

Commissioner for Patents Washington, DC 20231

## INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97 (b)(3)

Sir:

In compliance with the requirements of 37 C.F.R. 1.56 and 1.97(b)(3), submitted herewith on Form PTO-1449 is a list of publications known to Applicants and their Attorney/Agent. A copy of each publicly available document is also being submitted herewith.

Applicants have listed dates of publication on the attached PTO-1449 for the cited documents based on information presently available to the undersigned. However, the listed publication dates should not be construed as the dates the cited documents were actually published or otherwise publicly available.

This submission does not represent that a search has been made or that no better art exists. Nor does it constitute an admission that the cited documents are material or constitute "prior art." If the Examiner applies the listed documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents. Applicants further reserve the right to take

U.S. Application No.: 10/050,686

Page 2 of 2

appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the referenced documents be applied against the claims of the present application.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached Form 1449.

Under 37 C.F.R. § 1.97 (b)(3), this Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits; therefore, no fee is believed to be due in connection with this submission. However, the Commissioner is authorized to charge any deficiencies or credit any overpayment to/from our **Deposit Order Account**, No. 06-1448.

Should there be any questions after reviewing this paper, the Examiner is invited to contact the undersigned at (617) 832-1177.

Date: November 11, 2002

Customer No.: 25181

Patent Group Foley Hoag LLP 155 Seaport Boulevard Boston, MA 02210-2600

Phone: (617) 832-1000 Fax: (617) 832-7000 Respectfully Submitted,

Isabelle Clauss, Ph.D.

Reg. No. 47,326

Agent for Applicants

Sheet Page 1 of 3 Docket Number (Optional) Form PTO-1449 Application Number HMV-070.01 10/050,686 INFORMATION DISCLOSURE CITATION Applicant Goldberg, et al. IN AN APPLICATION (Use several sheets if necessary) Filing Date Group Art Unit January 16, 2002 1646 U.S. PATENT DOCUMEN FILING DATE EXAMIN DOCUMENT NUMBER DATE **CLASS SUBCLASS** IF APPROPRIATE ER NAME INITIAL lΑΑ 6,124,123 9/26/00 Bandman, et al. AB 6,001,619 12/14/99 Beach, et al. NOV 1 9 2002 AC 10/26/99 5,972,636 Goldberg AD **TECH CENTER 1600/2900** 6,087,122 07/11/00 Hustad, et al. AE 5,726,025 03/10/98 Kirschner, et al. AF 5,693,617 12/2/97 Stein, et al. FOREIGN PATENT DOCUMENTS Translation DOCUMENT NUMBER DATE COUNTRY **CLASS SUBCLASS** NO BA **OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages Etc.) Attaix, D., et al., "Regulation of ATP-Ubiquitin-Dependent Proteolysis in Muscle Wasting," Reprod. Nutr. Dev. 34: 583-597, (1994) CA Bartel et al., "The Recognition Component of the N-end Rule Pathway", The EMBO Journal, Vol. 9:3179-3189, (1990) CB Bodine, Sue C., et al., "Identification of Ubiquitin Ligases Required for Skeletal Muscle Atrophy", Science Magazine, November 2001, Vol. 294 CC Cenciarelli, C., et al., "Identification of a Family of Human F-Box Proteins", Current Biology, 9: 1177-1179 Supplementary material, October 11, CD Cenciarelli, C., et al., "Identification of a Family of Human F-Box Proteins, Current Biology, Vol. 9, No. 20, 1177-1179, October, 1999 CE Chiaur, D. S., et al., "Five Human Genes Encoding F-Box Proteins: Chromosome Mapping and Analysis in Human Tumors", Cytogenetics and Cell Genetics, 88: 255-258 (2000) CF

Craig, Karen L., et al. "The F-Box: A New Motif for Ubiquitin Dependent Proteolysis in Cell Cycle Regulation and Signal Transduction", Progress

Goldberg, Alfred L., et al., "The Cellular Chamber of Doom: Structures called Proteasomes Inside Cells Continuously Destroy Proteins. Several

Common Diseases Result When the Process Works Too Zealously - Or Not At All", Scientific American, Inc., 68-73, January, 2001.

Goldberg, Alfred L., "Probing the Proteasome Pathway", Nat Biotechnol., 18(5):494-6., May 2000

in Biophysics & Molecular Biology, 72:299-328, (1999)

CG

CH

CI

Form PTO-1449 INFORMATION DISCLOSURE CITATION	Docket Number (Optional) HMV-070.01	RECEIVED	Application Number 10/050,686
1	Applicant	E C Last V	
IN AN APPLICATION  Use several sheets if necessary)	Goldberg, et al.	NOV 1 9 2002	
	Filing Date January 16, 2002		Group Art Unit 1646
Goldberg, et al., "New Insights Into 378(3-4):131-40, March/April 1997	The Mechanisms and Impp	FOIA CENTER OF THE PARTY	Mular Protein Degradation" Biol Chem, Vo.
Goldberg, Alfred L., et al., "Function CK	ons of the Proteasome: the	Lysis at the End of the Tunnel" So	cience. Apr 28;268(5210):522-3, 1995.
CL Gomes, Marcelo D., et al. "Atrogin- 14440-14445, December 4, 2001.	I, A Muscle-Specific F-Box	x Protein Highly Expressed During	g Muscle Atrophy", PNAS, Vol. 98, No. 25,
CM Hershko, Avram, et al., "The Protein 261, No. 26, pp 11192-11999, Septen		he Ubiquitin-Protein Ligase Syster	n", The Journal of Biological Chemistry, Vol.
CN Jagoe, et al, "What Do We Really Kn 4(3):183-90, May 2001	ow About the Ubiquitin-Pr	oteasome Pathway in Muscle Atro	phy?", Curr Opin Clin Nutr Metab Care,
CO Kisselev, et al., "Proteasome Inhibito	rs: From Research Tools to	Drug Candidates" Chem Biol. (8)	:739-58, Aug. 8, 2001
Lecker, Stewart H., et al., "Muscle P. Nutr. 129(1S Suppl):227S-237S, Jan		Critical Role of the Ubiquitin-prote	easome Pathway in Normal and Disease States" J
CQ Lee, at al., "Proteasome Inhibitors: Vi	aluable New Tools for Cell	Biologists Trends" Cell Biol. (10)	:397-403. trends in Cell Biology(Review), Vol.
CR Llovera M. et al., "Muscle Wasting a mediated Proteolysis", Int. J. Cancer		chexia is Linked to an Important A	ctivation of the ATP-Dependent Ubiquitin-
CS Lyapina, Svetlana A., et al. "Human C Proc. Natl. Acad. Sci, USA, Vol. 95, p			Complex (SCF) with SKP1 and an F-Box Protein,
Mitch et al., "Mechanisms of Muscle 335(25):1897-905, December 19, 199	Wasting. The Role of the V6.	Ubiquitin-proteasome Pathway", A	New England Journal of Medicine,
Patton, E. Elizabeth, et al., "Combina 243 (1998)	atorial Control in Ubiquitin	dependent Proteolysis: don't Skp	the F-box Hypothesis", Trends Genet. 14: 236-
Skowyra, Dorota, et al., "F-Box Prote 91, 209-219 October 17, 1997	ins Are Receptors that Rec	ruit Phosphorylated Substrates to t	he SCF Ubiquitin-Ligase Complex", Cell, Vol.
CW Solomon, et al., "Rates of Ubiquitin C Natl Acad Sci U S A, 95(21):12602-7		Muscles Atrophy, Largely Throug	th Activation of the N-end Rule Pathway", Proc
CX Tawa, et al., "Inhibitors of the Proteas 203, July 1, 1997.	some Reduce the Accelerate	ed Proteolysis in Atrophying Rat S	keletal Muscles" J Clin Invest., 100(1):197-
CY Voisin L. et al., "Muscle Wasting in a Proteasome Proteolytic Pathways", J.			on of Lysosomal, Ca <sup>2+</sup> -activated, and Ubiquitin-
. Winston, Jeffrey T., et al., "A Family	of Mammalian F-Box Prote	eins", Current Biology, 9: 1180-11	82, October 11, 1999

· .				Sheet Page 3 of
Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION Use several sheets if necessary)		N DISCLOSURE CITATION	Docket Number (Optional) HMV-070.01	Application Number 10/050,686
			Applicant Goldberg, et al.	
	4	. ,	Filing Date January 16, 2002	Group Art Unit 1646
Bodine, S. C., et al., GENBANK A	ccession No. AY059629, December 13, 2001	RECEIVED		
AN THE	A A			NOV 1 9 2002
TIENT	DB	Bodine, S. C., et al., GENBANK Ad	ccession No. AY059628, December 13, 2001	TECH CENTER 1800/200
	DC		Ligase Genes Expressed During Skeletal Muscle ol" Cold Spring Harbor Laboratory. May 2-6, 20	Atrophy," Abstracts of Papers Presented at the 2001 Meetin 01.
EXAMINE R			DATE CON	ISIDERED
			or not citation is in conformance with MPE is form with next communication to the app	P § 609; Draw line through citation if not in licant.

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE